Meningitis Treatment Market 2019 Industry Trends, Size, Share, Growth Insight, Leading Players, Competitive, Regional Analysis With Forecast To 2026
Meningitis is a swelling of the protective membranes covering the brain and spinal cord. It causes due to viral or bacterial infection of the fluid surrounding the brain. However, there are other reasons that can trigger meningitis such as brain tumor, cancer, injuries, and certain drugs. The swelling associated with meninges triggers symptoms such as painful headaches, fever, loss of appetite, and stiffness of the neck. Meningitis is a fatal disease and has a rapid onset of action. If left untreated, it can cause severe damage to the brain in almost half of the total infected population. It can also lead to serious ailments such as mental retardation, epilepsy, and deafness.
Download PDF Sample: https://www.coherentmarketinsights.com/insight/request-sample/954
According to Meningitis Research Foundation, as of 2017, around 80% – 90% of meningitis cases are estimated to be caused by enteroviruses and the remaining 10% is estimated to be caused by herpes virus, mumps, measles, and human immune deficiency virus. According to the Confederation of Meningitis Organizations Inc., in 2010, around 50% of the bacterial meningitis cases occur in children under the age of five years and in adolescent and young adults from 15-24 year of age.
Global Meningitis Treatment Market Taxonomy
By Causative Micro-organism
By Treatment Type
- Antibiotic Therapy
- Adjunctive Therapy
By Vaccine Type
- Meningococcal Conjugate Vaccine
- Meningococcal Polysaccharide Vaccine (MPSV4)
- Combination Vaccine
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/954
Innovation in technology to combat infectious diseases is expected to drive the future meningitis treatment market
Growing partnerships among public and private sectors, in order to increase availability of vaccine to the populace is expected to drive growth of the global meningitis treatment market. For instance, Global Alliance for Vaccines and Immunization (GAVIs), an international organization, brings together public and private sectors with a goal to provide access to all the latest vaccines to children in the world’s poorest countries. People suffering from immune compromised diseases such as HIV, cancer, diabetes, and organ transplants are at higher risk of contracting aseptic meningitis. Moreover, introduction of novel diagnostics and technological platforms are expected to drive growth of the global meningitis treatment market in the near future. For instance, in 2009, venture by Cadila with a U.S.-based vaccine company – Novavax, aimed to develop and manufacture therapeutic and prophylactic vaccines to combat infectious diseases. Furthermore, growing launch of new vaccine with improved mechanism and growing advancement in genetics and immunology are expected to boost growth of the global meningitis treatment market. High incidence of brain injuries due to road accidents are also driving the market growth.
However, strict regulatory policies and availability of alternate medications are expected to restrain growth of the global meningitis treatment market.
On the basis of geography, the global meningitis treatment market is expected to be the most prominent in the sub-Saharan belt of African, which is also known as the meningitis belt due to higher incidence rate of meningitis C. The second highest incidence rate is recorded in India as reported by the World Health Organization (WHO), 2015. Around 12,000 cases of meningitis C and 800 deaths were recorded in Nigeria, in 2015. This indicates the rising incidence rate of meningitis, which in turn, is expected to propel growth of the meningitis treatment market in the near future.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/meningitis-treatment-market-954
Global Meningitis treatment market is expected to gain momentum due to high cases of acute meningitis
The market is set to gain momentum due to current unmet needs of vaccinations and increasing incidence of meningitis globally. Joint ventures, collaborations, and investment in research and development activities by various companies are expected to boost growth of the market. For instance, to treat aseptic meningitis, Bristol-Myers Squib is focusing on development of biologics – nivolumab (Opdivo) is in phase 3, and ipilimumab in phase 2.
The key players operating in the global meningitis treatment market include Biomed Pvt. Ltd, Novartis, Nuron Biotech, Pfizer, Baxter, Merck & Co., GSK, and Sanofi.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire